On September 5, 2024, Pharvaris N.V. announced plans to initiate a Phase 3 study of deucrictibant for treating hereditary angioedema and presented positive data showing a 93% reduction in attack rates during a long-term extension study. This event is considered significant for investors, reflecting positive sentiment regarding ongoing clinical developments.